Business

Holding(s) in Company

M&G Plc has notified Ondine Biomedical Inc. of a movement in its major holding, crossing a threshold on February 11, 2026. The total voting rights held by M&G Plc now stand at 13.041900%, representing 67,604,901 voting rights attached to shares, an increase from its previous notification of 12.974380%. This change is attributed to a movement of 1% as per the company's articles. Disclaimer*

Ondine Biomedical, Inc.February 20, 20263
Holding(s) in Company

About this update from Ondine Biomedical, Inc.

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN CA68234M2058 Issuer Name ONDINE BIOMEDICAL INC UK or Non-UK Issuer Non-UK 2. Reason for Notification Other Comments Movement of 1% as per Articles 3. Details of person subject to the notification obligation Name M&G Plc City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above   City of registered office (if applicable)   Country of registered office (if applicable)   5. Date on which the threshold was crossed or reached 11-Feb-2026 6. Date on which Issuer notified 12-Feb-2026 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached 13.041900 0.000000 13.041900 67604901 Position of previous notification (if applicable) 12.974380 0.000000 12.974380 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached 8A. Voting rights attached to shares Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1) CA68234M2058 67604901 13.041900 Sub Total 8.A 67604901 13.041900% 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights   Sub Total 8.B1 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b)) Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights   Sub Total 8.B2 9. Information in relation to the person subject to the notification obligation 2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary) Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold M&G Plc M&G Plc (Parent company) 13.041900% 13.041900% M&G Plc M&G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&G Plc) 13.041900% 13.041900% M&G Plc M&G Group Limited (wholly owned subsidiary of M&G Group Regulated Entity Holding Company Limited) 13.041900% 13.041900% M&G Plc M&G FA Limited (wholly owned subsidiary of M&G Group Limited) 13.041900% 13.041900% M&G Plc M&G Investment Management Limited (wholly owned subsidiary of M&G FA Limited) 13.041900% 13.041900% 10. In case of proxy voting Name of the proxy holder   The number and % of voting rights held   The date until which the voting rights will be held   11. Additional Information   12. Date of Completion 12-Feb-2026 13. Place Of Completion London, United Kingdom

View stock analysis, news, and events for Ondine Biomedical, Inc.

More from Ondine Biomedical, Inc.

All Ondine Biomedical, Inc. news →